Figure 2From: A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss Estimated Incremental Cost Utility Ratio at various compliance losses after generic substitution. *At a willingness to pay of €40,000 per QALY gained.Back to article page